Jump to navigation
Search form
Search
Selcia
Drug Discovery & Radiolabelling
Home
About Selcia
Key Facts
Our Approach
Senior Management
Facilities & Accreditations
History
Drug Discovery
Medicinal Chemistry
Natural Product Chemistry and Structural Biology
Assay Development and Screening
ADME/PK
PPIase Services
Target Class and Disease Expertise
Radiolabelling
C-14 Custom Radiolabelling
14C-Isotope of choice
Carbon-14 API to GMP
GLP Analytical and Metabolite Synthesis
Quality System
Techniques & Equipment
Industries
Registration Studies using 14C
REACH – 14C-Regulatory requirements
Chemistry & Analytics
Custom Synthesis
Crop Science Expertise
Analytical and Separation Sciences
News & Events
Resources
Literature
Selcia Brochures
Partners
Careers
Contact Us
2018 News | Events | Industry Updates
25 January 2018
Selcia Joins Eurofins Group
09 January 2018
Cypralis and Gilead Sciences, Inc. agree on license terms for rights to certain macrocyclic inhibitors synthesised during a drug discovery collaboration between Gilead (Foster City, California) and Selcia Ltd.
Pages
« first
‹ previous
1
2
Selcia is now part of Eurofins.
Read the
press release
to find out more.
X
